Method of making recombinant human antibodies for use in biosensor technology

• US 20060286548A1
• Filed: 06/16/2005
• Published: 12/21/2006
• Est. Priority Date: 06/16/2005
• Status: Abandoned Application

• Current Assignee: GTC Biotherapeutics, Inc.
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Liposky, Gregory, Olsen, Byron V.
• Application Number:
  US11/156,831
• Publication Number:
  US 20060286548A1
• Time in Patent Office: Days
• US Class Current: 435/5
• CPC Class Codes: G01N 2469/10 Detection of antigens from microorganism in sample from host
• CPC Class Codes: G01N 33/6842 Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

According to the current invention and apparatus and methods are provided for the production of modified antibodies and calins for use in biosensor applications.

Claims

1. A method for detecting the presence of at least one biological agent of interest in a sample, said method comprising:

(a) combining said sample with a composition comprising a population of biosensor antibodies, wherein

i. said biosensor antibodies are bound to a solid support;

ii. the population of said biosensor antibodies comprises antibodies directed to at least one biological agent of interest in said sample;

(b) capturing any biological agents of interest;

(c) identifying any biological agents of interest present in said sample; and

,

(d) reporting the capture of said at least one biological agent of interest.

2. The method according to claim 1, wherein said at least one biological agent of interest is present in the environment in an aerosolized form prior to capture in said sample.

3. The method according to claim 1, wherein said at least one biological agent of interest is present in the environment in an aqueous solution prior to capture in said sample.

4. The method according to claim 1, wherein said at least one biological agent of interest is present in the environment in an food substance prior to capture in said sample.

5. The method according to claim 1, wherein said at least one biological agent is contacted by biosensor calins instead of antibodies.

6. The method according to claim 1, wherein said at least one biological agent may contacted by a biosensor calins in addition to a biosensor antibody.

7. The method according to claim 1, wherein said population of biosensor antibodies represents at least two discrete subpopulations each directed towards the detection of a different biological agent of interest.

8. The method according to claim 1, wherein said biosensor antibodies are produced in the milk of transgenic mammals.

9. The method according to claim 1, wherein biosensor antibodies detect the presence of one or more pathogenic organisms.

10. The method according to claim 1, wherein said population of biosensor antibodies represents at least ten discrete subpopulations each directed towards the detection of a different biological agent.

11. The method according to claim 1, wherein said biological agents detected are polypeptides, proteins, chemical agents or DNA sequences produced by food contaminating organisms.

12. The method according to claim 1, further comprising:

immobilizing each of said populations of biosensor antibodies on said solid support at a known, predetermined position on said solid support such that each of said antibodies can be identified by the position where it is immobilized and upon capture of a target analyte can report such capture to a user; and

,

a reporting means for the capture of a said target analyte;

wherein upon mobilization of each of said populations of biosensor antibodies on said solid support at a known, predetermined position said biosensor antibodies are also oriented so as to optimize capture of said target analyte.

13. The method of claim 1, wherein said reporting means utilizes a secondary antibody for detection and reporting.

14. The method of claim 1, wherein said reporting means comprises mass spectrometry.

15. The method of claim 1, wherein said reporting means comprises a visible indication.

16. The method of claim 1, wherein said reporting means comprises a qualitative indication.

17. The method of claim 1, wherein said reporting means comprises a quantitative indication.

18. The method of claim 1, wherein said reporting means comprises a fusion antibody with a detectable tag.

19. The method of claim 18, wherein said tag is a fluorescent antibody.

20. The method of claim 1, wherein said support is made of materials selected from the group consisting of nitrocellulose, nylon, polyvinylidene difluoride, mica, silicon, glass, metal, metal coating or plastics, and its derivatives.

21. The method of claim 1, wherein the number of said antibodies immobilized on said solid support ranges from 10 to 500 different kinds.

22. The method of claim 1, wherein the number of said antibodies immobilized on said solid support ranges from 500 to 1,000 different kinds.

23. The support of claim 20, further comprising patterning the surface with a film of hydrophobic molecules.

24. The support of claim 20 wherein said hydrophobic molecules include biotin or biotin derivatives to form a said uniform biological layer such that capture antibodies can be bound to the biotinylated surface.

25. The support of claim 20 wherein the metal or metal coating of said solid support is selected from the group consisting of platinum, silver, copper, gold and combinations thereof.

26. The support of claim 24 wherein the biotin-binding molecules are streptavidin or streptavidin derivatives attached to capture antibodies.

27. The method of claim 1 wherein said at least one biological agent of interest is a target biological analyte molecule selected from or produced by one the following group:

pathogenic bacteria, colonic bacteria, viruses, parasites, bacterial toxins, fungi, enzymes.

28. The method of claim 1 wherein said at least one biological agent of interest includes molecular toxins or chemicals selected from the group including:

ricin;

sarin;

soman, tabun;

cyanogens;

chloride and hydrogen chloride;

oleoresin capsicum;

arsene;

chlorine, diphosgene;

phosgene;

distilled mustard, ethyldichloroarsine, mustard-lewisite mixture;

nitrogen mustard;

organophosphate pesticides;

aflatoxin;

Trichothecene mycotoxins, and the Staphylococcus enterotoxins A, B and C.

29. The method of claim 27 wherein the pathogenic organism of interest is a target biological agent of interest and is selected from group including:

Bacillus Anthracis;

Yersina Pestis;

Yersina enterocolitica;

Francisella Tularensis;

Vibrio Cholerae;

Vibrio parahemolyticus;

Klebsiella species;

Pseudomonas aeruginosa;

Streptococci;

Listeria;

Cryptosporidium;

Venezuelan Equine Encephalitis, Filoviridae (Ebola and Marburg viruses specifically);

Brucella abortus;

Brucella melitensis;

Brucella suis;

Nipah virus;

Hendra virus (formerly called equine morbillivirus);

Flaviviruses;

Burkholderia mallei (formerly known as Pseudomonas mallei);

Smallpox varieties or orthopoxvirus [two forms;

variola major and variola minor];

Coxiella burnetii;

Arenaviridae (Lassa fever, Argentine and Bolivian hemorrhagic fever), the Bunyaviridae (Hantavirus, Congo-Crimean hemorrhagic fever, Rift Valley fever, and Yellow fever) families;

the Dengue hemorrhagic fever virus;

Aeromonas sobria;

Aeromonas hydrophila;

Aeromonas caviae;

Escherichia coli;

Salmonella typhi;

Salmonella paratyphi;

Salmonella enteriditis;

Salmonella cholera-suis;

Salmonella typhimurium;

Salmonella heidelberg;

Shigella sonnei;

Shigella flexneri;

Shigella boydit;

Shigella dysenteriae;

Mycobacterium tuberculosis;

Yersinia enterocolitca;

Aeromonas hydrophila;

Plesiomonas shigelloides;

Campylobacteria jejuni;

Campylobacreria coli;

Bacteroides fragilis;

Clostridia septicum;

Clostridia perfingens;

Clostridia botulinum;

and Clostridia difficile.

30. The method of claim 1, wherein the number of biological agents of interest detected is at least 2.

31. The method of claim 1, wherein the number of biological agents of interest detected is in a range of between 10 and 100.

32. The method of claim 8, further comprising the production a single type of biosensor antibody in the milk of one or more transgenic mammals at a production volume of at least 3 grams per liter of milk produced.

33. The method of claim 8,,further comprising the production a single type of biosensor antibody in the milk of one or more transgenic mammals at a production volume of at least 10 grams per liter of milk produced.

34. The method of claim 12, wherein at least one subpopulation of said biosensor antibodies have a cyclized peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

35. The method of claim 12, wherein at least one subpopulation said biosensor antibodies have at least one peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

36. The method of claim 34 or 35, wherein said cyclized peptide or said peptide is between 5 and 15 amino acids in length.

37. The method of claim 12, wherein at least one subpopulation of said biosensor antibodies are truncated to provide for improved means of attachment and orientation to a solid support without substantially affecting their physiological ability to bind a target analyte.

38. The method of claim 8, further comprising the production a single type of biosensor antibody in the milk of one or more transgenic mammals wherein said biosensor antibody has a truncated sequence on its Fc end that will allow improved attachment to a solid support without substantially affecting their physiological ability to bind a target analyte.

39. The method of claim 1 wherein said at least one biological agent of interest is a target biological analyte molecule produced by a pathogenic organism found in food.

40. The method of claim 8, wherein the antibodies produced by a transgenic mammal have their amino acid sequences altered to provide for a cyclized peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

41. The method of claim 8, wherein the antibodies produced by a transgenic mammal have their amino acid sequences altered to provide for at least one peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

42. The method of claim 8, wherein the antibodies produced by a transgenic mammal have their amino acid sequences altered to provide for an antibody sequence that is truncated to provide for improved means of attachment and orientation to a solid support without substantially affecting its physiological ability to bind a target analyte.

90. The method of claim 1 wherein said at least one biological agent of interest includes agents of interest including:

vomiting agents, blister agents, blood agents, chemical warfare agents, choking agents, incapacitating agents and tear agents.

43. A biosensor apparatus for detecting the presence of at least one biological agent of interest in a sample, said apparatus comprising:

(a) means for taking a sample and thereafter combining said sample with a composition comprising a population of biosensor antibodies, wherein

i. said biosensor antibodies are bound to a solid support;

ii. the population of said biosensor antibodies comprises antibodies directed to at least one biological agent of interest in said sample;

(b) means for capturing any biological agents of interest;

(c) means for identifying any biological agents of interest present in said sample; and

,

(d) means for reporting the capture of said at least one biological agent of interest.

44. The apparatus according to claim 43, wherein said at least one biological agent of interest is present in the environment in an aerosolized form prior to capture in said sample.

45. The apparatus according to claim 43, wherein said at least one biological agent of interest is present in the environment in an aqueous solution prior to capture in said sample.

46. The apparatus according to claim 43, wherein said at least one biological agent of interest is present in the environment in a food substance prior to capture in said sample.

47. The apparatus according to claim 43, wherein said at least one biological agent is contacted by biosensor calins instead of antibodies.

48. The apparatus according to claim 43, wherein said at least one biological agent may contacted by a biosensor calins in addition to a biosensor antibody.

49. The apparatus according to claim 43, wherein said population of biosensor antibodies represents at least two discrete subpopulations each directed towards the detection of a different biological agent of interest.

50. The apparatus according to claim 43, wherein said biosensor antibodies are produced in the milk of transgenic mammals.

51. The apparatus according to claim 43, wherein biosensor antibodies detect the presence of one or more pathogenic organisms.

53. The apparatus according to claim 43, wherein said biological agents detected are polypeptides, proteins, chemical agents or DNA sequences produced by food contaminating organisms.

54. The apparatus according to claim 43, further comprising:

immobilizing each of said populations of biosensor antibodies on said solid support at a known, predetermined position on said solid support such that each of said antibodies can be identified by the position where it is immobilized and upon capture of a target analyte can report such capture to a user; and

,

a reporting means for the capture of a said target analyte;

wherein upon mobilization of each of said populations of biosensor antibodies on said solid support at a known, predetermined position said biosensor antibodies are also oriented so as to optimize capture of said target analyte.

55. The apparatus of claim 43, wherein said reporting means utilizes a secondary antibody for detection and reporting.

56. The apparatus of claim 43, wherein said reporting means comprises mass spectrometry.

57. The apparatus of claim 43, wherein said reporting means comprises a visible indication.

58. The apparatus of claim 43, wherein said reporting means comprises a qualitative indication.

59. The apparatus of claim 43, wherein said reporting means comprises a quantitative indication.

60. The apparatus of claim 43, wherein said reporting means comprises a fusion antibody with a detectable tag.

61. The apparatus of claim 60, wherein said tag is a fluorescent antibody.

62. The apparatus of claim 43, wherein said support is made of materials selected from the group consisting of nitrocellulose, nylon, polyvinylidene difluoride, mica, silicon, glass, metal, metal coating or plastics, and its derivatives.

63. The apparatus of claim 43, wherein the number of said antibodies immobilized on said solid support ranges from 10 to 500 different kinds.

64. The apparatus of claim 43, wherein the number of said antibodies immobilized on said solid support ranges from 500 to 1,000 different kinds.

65. The support of claim 62, further comprising patterning the surface with a film of hydrophobic molecules.

66. The support of claim 62 wherein said hydrophobic molecules include biotin or biotin derivatives to form a said uniform biological layer such that capture antibodies can be bound to the biotinylated surface.

67. The support of claim 62 wherein the metal or metal coating of said solid support is selected from the group consisting of platinum, silver, copper, gold and combinations thereof.

68. The support of claim 66 wherein the biotin-binding molecules are streptavidin or streptavidin derivatives attached to capture antibodies.

69. The apparatus of claim 43 wherein said at least one biological agent of interest is a target biological analyte molecule selected from or produced by one the following group:

pathogenic bacteria, colonic bacteria, viruses, parasites, bacterial toxins, fungi, enzymes.

70. The apparatus of claim 43 wherein said at least one biological agent of interest includes molecular toxins or chemicals selected from the group including:

ricin;

sarin;

soman, tabun;

cyanogens;

chloride and hydrogen chloride;

oleoresin capsicum;

arsene;

chlorine, diphosgene;

phosgene;

distilled mustard, ethyldichloroarsine, mustard-lewisite mixture;

nitrogen mustard;

organophosphate pesticides;

aflatoxin;

Trichothecene mycotoxins, and the Staphylococcus enterotoxins A, B and C.

71. The apparatus of claim 69 wherein the pathogenic organism of interest is a target biological agent of interest and is selected from group including:

Bacillus Anthracis;

Yersina Pestis;

Yersina enterocolitica;

Francisella Tularensis;

Vibrio Cholerae;

Vibrio parahemolyticus;

Klebsiella species;

Pseudomonas aeruginosa;

Streptococci;

Listeria;

Cryptosporidium;

Venezuelan Equine Encephalitis, Filoviridae (Ebola and Marburg viruses specifically);

Brucella abortus;

Brucella melitensis;

Brucella suis;

Nipah virus;

Hendra virus (formerly called equine morbillivirus);

Flaviviruses;

Burkholderia mallei (formerly known as Pseudomonas mallei);

Smallpox varieties or orthopoxvirus [two forms;

variola major and variola minor];

Coxiella burnetii;

Arenaviridae (Lassa fever, Argentine and Bolivian hemorrhagic fever), the Bunyaviridae (Hantavirus, Congo-Crimean hemorrhagic fever, Rift Valley fever, and Yellow fever) families;

the Dengue hemorrhagic fever virus;

Aeromonas sobria;

Aeromonas hydrophila;

Aeromonas caviae;

Escherichia coli;

Salmonella typhi;

Salmonella paratyphi;

Salmonella enteriditis;

Salmonella cholera-suis;

Salmonella typhimurium;

Salmonella heidelberg;

Shigella sonnei;

Shigella flexneri;

Shigella boydit;

Shigella dysenteriae;

Mycobacterium tuberculosis;

Yersinia enterocolitca;

Aeromonas hydrophila;

Plesiomonas shigelloides;

Campylobacteria jejuni;

Campylobacreria coli;

Bacteroides fragilis;

Clostridia septicum;

Clostridia perfingens;

Clostridia botulinum;

and Clostridia difficile.

72. The apparatus of claim 43, wherein the number of biological agents of interest detected is at least 2.

73. The apparatus of claim 43, wherein the number of biological agents of interest detected is in a range of between 10 and 100.

75. The apparatus of claim 50, further comprising the production a single type of biosensor antibody in the milk of one or more transgenic mammals at a production volume of at least 3 grams per liter of milk produced.

76. The apparatus of claim 50, further comprising the production a single type of biosensor antibody in the milk of one or more transgenic mammals at a production volume of at least 10 grams per liter of milk produced.

77. The apparatus of claim 54, wherein at least one subpopulation of said biosensor antibodies have a cyclized peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

78. The apparatus of claim 54, wherein at least one subpopulation said biosensor antibodies have at least one peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

79. The apparatus of claim 76 or 77, wherein said cyclized peptide or said peptide is between 5 and 15 amino acids in length.

80. The apparatus of claim 54, wherein at least one subpopulation of said biosensor antibodies are truncated to provide for improved means of attachment and orientation to a solid support without substantially affecting their physiological ability to bind a target analyte.

81. The apparatus of claim 50, further comprising the production a single type of biosensor antibody in the milk of one or more transgenic mammals wherein said biosensor antibody has a truncated sequence on its Fc end that will allow improved attachment to a solid support without substantially affecting their physiological ability to bind a target analyte.

82. The apparatus of claim 43 wherein said at least one biological agent of interest is a target biological analyte molecule produced by a pathogenic organism found in food.

83. The apparatus of claim 50, wherein the antibodies produced by a transgenic mammal have their amino acid sequences altered to provide for a cyclized peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

84. The apparatus of claim 50, wherein the antibodies produced by a transgenic mammal have their amino acid sequences altered to provide for at least one peptide added to their Fc sequence to provide for additional means of attachment and orientation to a solid support.

85. The apparatus of claim 50, wherein the antibodies produced by a transgenic mammal have their amino acid sequences altered to provide for an antibody sequence that is truncated to provide for improved means of attachment and orientation to a solid support without substantially affecting its physiological ability to bind a target analyte.

86. The apparatus of claim 43 further comprising an electrostatic impeller to aid in the collection of particulates for sampling.

87. The apparatus of claim 43 wherein the biosensor array is further comprised of replaceable units detachable from said apparatus each unit comprising known subpopulations of biosensor antibodies.

88. The apparatus of claim 43 further comprising where individual antibody subpopulations are immobilized at a known, predetermined position on said solid support such that one or more subpopulations can be removed from the biosensor antibody detection system and replaced individually.

89. The apparatus of claim 43 wherein said biosensor antibody signals are operatively connected to a reporting means and can report the detection of the target biological analyte upon antibody capture.

91. The apparatus of claim 43 wherein said at least one biological agent of interest includes agents of interest including:

vomiting agents, blister agents, blood agents, chemical warfare agents, choking agents, incapacitating agents and tear agents.

52. The apparatus according to ciaim 43, wherein said population of biosensor antibodies represents at least ten discrete subpopulations each directed towards the detection of a different biological agent.

92. A method for detecting the presence of at least one biological agent of interest in a sample, said method comprising:

(a) combining said sample with a composition comprising a population of biosensor calins, wherein

i. said biosensor calins are bound to a solid support;

ii. the population of said biosensor calins comprises calins directed to at least one biological agent of interest in said sample;

(c) identifying any biological agents of interest present in said sample; and

,

(d) reporting the capture of said at least one biological agent of interest.

93. An apparatus for detecting the presence of at least one biological agent of interest in a sample, said method comprising:

(a) combining said sample with a composition comprising a population of biosensor calins, wherein

i. said biosensor calins are bound to a solid support;

ii. the population of said biosensor calins comprises calins directed to at least one biological agent of interest in said sample;

(b) capturing any biological agents of interest;

(c) identifying any biological agents of interest present in said sample; and

,

(d) reporting the capture of said at least one biological agent of interest.